Cidara Therapeutics Inc expected to post a loss of $3.54 a share - Earnings Preview

Cidara Therapeutics

06/05/2025 21:15

Cidara Therapeutics Inc CDTX.OQ CDTX.O is expected to show a fall in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

​LSEG's mean analyst estimate for Cidara Therapeutics Inc is for a loss of $3.54 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cidara Therapeutics Inc is $35.00​, above​ its last closing price of $21.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-3.52
-3.62
-5.37
Missed
-48.3
Sep. 30 2024
-3.55
-4.25
-2.45
Beat
42.4
Jun. 30 2024
-4.01
-3.22
-1.39
Beat
56.9​
Mar. 31 2024
-0.20
-0.20
-2.28
Missed
-1,040
​​Dec. 31 2023
-2.07
-0.80
Beat
61.3
Sep. 30 2023
-3.19
-3.25
-1.80
Beat
44.6​
Jun. 30 2023
-2.04
-2.60
-2.80
Missed
-7.7
Mar. 31 2023
-0.41
-0.73
0.60
Beat
181.8

This summary was machine generated May 6 at 20:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)